CV0601
/ CureVac, GSK
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
September 21, 2024
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
(clinicaltrials.gov)
- P2 | N=675 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
January 16, 2024
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
(clinicaltrials.gov)
- P2 | N=664 | Active, not recruiting | Sponsor: GlaxoSmithKline | N=427 ➔ 664
Enrollment change • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
November 14, 2023
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
(clinicaltrials.gov)
- P2 | N=427 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2024 ➔ Sep 2024 | Trial primary completion date: Mar 2024 ➔ Sep 2024
Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
September 06, 2023
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
(clinicaltrials.gov)
- P2 | N=415 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
July 27, 2023
A Study on the Safety and Immune Response of a Booster Dose of Investigational COVID-19 mRNA Vaccines in Healthy Adults
(clinicaltrials.gov)
- P2 | N=415 | Not yet recruiting | Sponsor: GlaxoSmithKline
New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 5
Of
5
Go to page
1